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Abstract 
Objective: To examine the efficacy of neurofeedback (NF), behavior therapy (BT) and 
pharmacology (PH) on ADHD. Method: 59 children with ADHD (M = 8.80 yrs., SD = 1.92) 
were randomly assigned to one of the three treatments in a pre-post assessment design. 
Mothers and teacher rated ADHD scales, and children were assessed using The Integrated 
Visual and Auditory Continuous Performance Test (IVA/CPT). Results: The three treatments 
were effective on IVA/CPT, but with different trends. BT and especially NF got 
improvement in response control and attention, and PH mainly in visual attention. On rating 
scales, BT improved all measures, and NF and PH had a minor but interesting influence. 
Conclusions: From a global point of view behavior therapy has the most extensive results, 
but PH has the greatest capacity to improve overall attention, and NF is able to improve both 
control response and inattention. Clinical implications are discussed. 
 
Keywords: randomized controlled trial, neurofeedback, pharmacological treatment, 
behavior therapy, attention deficit/hyperactivity disorder (ADHD), IVA/CPT, rating scales.  
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A randomized controlled trial to examine the post-treatment efficacy of neurofeedback, 
behavior therapy, and pharmacology on ADHD measures 
Attention deficit hyperactivity disorder (ADHD) is one of the most common 
neurodevelopmental disorders during childhood and adolescence, with a worldwide 
prevalence about 5%, that severely affects schooling, family and social life and is 
characterized by symptoms such as inattention, hyperactivity and impulsiveness (APA, 
2013). Pharmacological treatment is the option that is usually recommended in these cases. 
However, stimulant medications are not always accepted by parents, children or doctors due 
to the possible adverse effects (Peterson, McDonagh, & Fu, 2008).  
Empirical studies generally compared the efficacy of pharmacological treatment with 
other therapy options. So, Leung and Hung (2008) in their study indicated that the 
combination of methylphenidate and behavioral therapy was significantly more efficacious 
reducing the symptoms of ADHD than pharmacological treatment alone. These findings have 
been corroborated by Eiraldi, Mautone, & Power (2012). 
The MTA found that symptoms normalized in 68% of children treated with both 
stimulant medications and behavioral interventions (Lofthouse, Arnold, Hersch, Hurt, & 
deBeus, 2012). Thus, a combined application of both is recommended, especially for school-
age children with combined ADHD subtype (Murray et al., 2008) and when the characteristic 
symptoms and impairment of the child’s general functioning are severe (NICE, 2013) 
(National Institute for Health & Clinical Excellence, 2013).  
Regarding non-pharmacological interventions in the treatment of ADHD, such as 
psychological treatments, Fabiano et al. (2009) and Willis, Weyandt, Lubiner, & Schubart 
(2011), showed that behavioral therapy (applied as parent training or classroom management) 
is viable and effective in ADHD treatment. Hodgson, Hutchinson and Denson (2012) 
replicated and expanded the Fabiano et al. (2009) meta-analysis, and compared the efficacy 
Running head: A RANDOMIZED CONTROLLED TRIAL TO EXAMINE THE POST TREATMENT EFFICACY 4 
 
 
 
 
of seven non-pharmacological interventions that included, behavioral modification, 
neurofeedback, school programs and parent training, concluding that such treatments have 
considerable potential in the treatment of children with ADHD. More specifically, the meta-
analysis of Coates, Taylor and Sayal (2015) suggests that parenting interventions for ADHD 
are effective. 
The efficacy of neurofeedback as a viable option to treat ADHD in relation to 
pharmacological treatment has been researched in different studies, randomized controlled 
trials, and meta-analysis yielding promising results to date (Arns, Heinrich, & Sthehl, 2014; 
Arns, Ridder, Strehl, Breteler, &Coenen, 2009; Duric, Assmus, Gundersen, & Elgen, 2012; 
Leins et al., 2007; Lofthouse et al., 2012). In a randomized controlled trial, neurofeedback 
training was found to be superior to a computerized attention skills training (Gevensleben et 
al., 2009). Duric et al. (2012) in a controlled and randomized clinical trial found that 
neurofeedback treatment seemed to improve the core symptoms of ADHD, as assessed by 
parental reports. When neurofeedback was administered in conjunction with pharmacological 
treatment, medication dose originally prescribed has been observed to decrease (Lora & 
Moreno, 2011) and Meisel, Servera, Garcia-Banda, Cardo and Moreno (2014) showed that 
effects were maintained for six months following treatment. Moreno-Garcia, Delgado-Pardo, 
Camacho-Vara de Rey, Meneres-Sancho, and Servera-Barceló (2015) showed that 
neurofeedback, pharmacological treatment and behavioral therapy are effective and cause 
similar effects in a specific electroencephalographic measure (theta/beta ratio).  
However, conclusions about the effectiveness of neurofeedback, especially compared 
with the best treatment (pharmacology and behavior therapy), are still controversial. For 
example, in their respective revisions, Pigott and Cannon (2014) concluded that 
neurofeedback is a useful treatment against stimulant medication and behavior therapy as 
first-line treatments, while Loo and Makeig (2012) only recognize that in recent years the 
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number and quality of research reports in neurofeedback have grown considerably, but the 
studies reviewed by them do not yet support this treatment as a first-line, stand-alone 
modality. In a similar vein, the Society of Clinical Child and Adolescent Psychology 
considers that neurofeedback is at Level 3 as a “possibly efficacious treatment” of ADHD 
(Evans, Owens, & Bunford, 2014). Therefore, many more studies are needed to know if 
neurofeedback can level up. 
One of the main methodological issues in comparing the effectiveness of these 
treatments could be the use of different measures of ADHD symptoms. Ratings scales for 
parents and teachers have been the most common procedure and often the only. However, it 
seems recommended to add at least some neuropsychological task. For example, the 
Integrated Visual and Auditory Continuous Performance Test (IVA/CPT) (Sandford & 
Turner, 2002) has been used to define attention and behavior problems by comparing children 
with a diagnosis of ADHD and children with no history of the disorder (Moreno, Pardo, & 
Roldán, 2015), and to evaluated the efficacy of neurofeedback ( (Moreno, Pardo, Aires, & 
Meneres, 2013; Yan et al., 2008) . 
This is the background for this study, which aims to compare the differential efficacy 
of neurofeedback, pharmacological intervention and behavior therapy in ADHD symptoms 
measured by rating scales and neuropsychological variables. The specific objectives are the 
following: a) Determine the efficacy of neurofeedback, behavior therapy and 
pharmacological treatment on ADHD symptomatology using computerized (IVA/CPT) 
assessment tools and rating scales administered to parents and teachers and b) Compare the 
effects of neurofeedback versus behavior therapy and pharmacological treatment in 
attentional and behavioral variables, from three independent sources of information: children 
with a diagnosis of ADHD, parents and teachers. 
Method 
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Participants 
In the screening phase, 146 children with ADHD were recruited from the pediatric 
primary care units of a Health District of Sevilla (Spain). Of all these children 35 declined to 
participate and 52 were excluded for not meeting the inclusion criteria (see Figure 1): 1) 
being between 7 and 14 years old, 2) presenting a score above the 90th percentile in the 
teacher ADHD Rating Scale-IV and above the 80th percentile in the parents’ version, 3) 
patients being drug-naïve before the first consultation, 4), not presenting evidence of 
psychiatric disability or mental retardation (Kauffman Brief Intelligence Test), 5), not present 
comorbid disorders with ADHD (Child Behavior Checklist, CBCL) and 6) patients with no 
history of medical illness, chronic medical illness or current medical illness that may 
contraindicate pharmacological treatment. 
PLEASE INSERT FIGURE 1 ABOUT HERE 
 The remaining 59 children were randomized to one of the conditions of administered 
treatments. During treatment two children dropped out. Therefore, 57 children completed the 
study (19 in each of the three treatments). The Human Research Ethics Committee of the 
University of Sevilla approved previously this investigation, and informed consent was 
obtained in all cases. Table 1 shows the participants’ descriptive data. 
PLEASE INSERT TABLE 1 ABOUT HERE 
Materials and Procedure 
 Integrated Visual and Auditory Continuous Performance Test (IVA/CPT) (Sandford 
& Turner, 2002). This tool evaluates attention and control of responses to auditory and visual 
stimuli. The results are presented in standardized coefficients with an average score of 100 
and a typical deviation of 15. We analyzed three global scales related to response control 
(Full Scale Response Control, Auditory Response Control, and Visual Response Control), 
and three others related to attention (Full Scale Attention, Auditory Attention, and Visual 
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Attention). We also analyzed the primary care scales (both with auditory stimuli as visual) 
related with response control and attention. Response control: Prudence (comission errors), 
Consistency (ability to respond reliably based in reaction time), and Stamina (ability to 
sustain speed of response by comparing the mean reaction time of the first 200 versus the last 
200 trials). Attention: Vigilance (omissions), Focus (Reaction Time Variability), and Speed 
(Hits Reaction Time). 
 ADHD-Rating Scales-IV (ADHD RS-IV) (DuPaul, Power Anastopoulos, and Reid, 
1998). It consists of 18 items that comprises two subscales, inattention and hyperactivity-
impulsivity, and a total score. Mothers and teachers completed this scale. The higher the 
score, the higher the problems related with ADHD. 
 Attention Deficit Disorders Evaluation Scale (ADDES) (McCarney and Arthaud, 
2004). Parents were asked to complete this scale separately, in order to evaluate inattentive 
and hyperactive/impulsive symptoms in a more extensive way than with the ADHD RS-IV 
scale. 
 
Procedure 
  This is a design of an open randomized controlled group with pre- and post -
treatment phases. Participants were randomly assigned to three experimental conditions 
corresponding to administered treatments (neurofeedback, behavioral therapy and 
pharmacology), and were evaluated with the same instruments and under identical conditions 
before and after therapeutic intervention. Pre-treatment evaluation was done approximately 
one week before treatment began, and post-treatment evaluation was done when the 
intervention was complete in all cases, i.e. after 20 weeks of intervention. In no case other 
treatments were administered simultaneously. 
Treatment groups  
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   Neurofeedback training (NF). This treatment was conducted using Atlantis II 2x2 
equipment from Brainmaster, with an impedance check (below 5 Kohms) which 
automatically controls artifacts (>120 microvolts). EEG was analyzed in two frequency bands 
(theta: 4-7 Hz, beta: 15-20 Hz). EEG recordings were obtained using the monopolar signal Cz 
for participants between the ages of 7-11 and for older participants, EEG recordings used 
monopolar signal FCz, based on the International 10-20 system with ear references. 
Following the guidelines for the recommended treatment program (Monastra et al., 2005) 
participants received 4 Theta/Beta training sessions per week for a total of 40 sessions, 
wherein each session consisted of six four-minute runs, and at the beginning of each session 
baseline values were determined (30 seconds). Each session began with a previous period (2-
5 minutes) for the purpose of get familiar with the procedure. Later, periods of training and 
EEG feedback, with an initial duration of 120 seconds were developed, that increased 
according to the learning curves of each child. Participants were rewarded for 70% of the 
time below the threshold in Theta, and up to 20% of the time below the threshold in Beta. 
Behavioral Therapy (BT). Participants assigned to the behavioral therapy group 
received an intervention consisted in parent training including 10 group sessions, teacher 
training including 5 training sessions, and individualized children treatment including 15 
individualized sessions of cognitive therapy, each lasting 50 minutes. Parents participated in 
weekly 90-minute sessions based on the Parent Training Program (Barkley, 1997). Each 90-
minute teachers group sessions focused on two aspects, training on behavior modification 
strategies in the classroom (3 sessions) and specific curricular adaptations for ADHD (2 
sessions) (Eiraldi et al., 2012). Teachers and parents received advice on implementing and 
reinforcing the behavior strategies acquired at home and at school. 
 Pharmacological Treatment (PH). Participants assigned to pharmacological 
treatment group received the ADHD treatment prescribed by the pediatrician that conducted 
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their follow-up during referred 20 weeks. Pharmacological intervention has been adjusted to 
a common action protocol which included analytical, physical and neurological examination, 
somatometry and initial assessment of intensity of ADHD symptoms prior to treatment, as 
well as periodical dosage revision and recorded side effects. All patients received 
methylphenidate in its different formulations (immediate, intermediate release or OROS).  
Data Analysis 
With regard to the first objective, which focuses on the therapeutic change of the 
different treatments separately in relation to the two evaluation periods (pre- and post-
treatment), a comparison of means was done for related groups (Paired Samples T-Test) and 
in absence of the required assumptions, Wilcoxon t tests were applied. For the second 
objective, where the differential efficacy of the three therapeutic options was examined, an 
analysis of variance (single factor ANOVA) was done, and the subsequent post-hoc contrasts 
were done between the treatments, with the Bonferroni correction to control the alpha error. 
In absence of the required model assumptions, Welch test or non-parametric Kruskal Wallis 
were applied. 
As a measure of the efficacy of each treatment, the difference between the pre and 
post-treatment means (the “change” variable) was used, and effect sizes (Cohen´s d) were 
calculated. Thus, the results presented arise from comparing and contrasting 3 treatments 
(NF, BT, and PH) x three sources of information (children, mothers and teachers) x three 
different instruments; IVA/CPT, ADHD RS-IV, and ADDES. 
Results 
Comparing pre and post-treatment assessments. 
Tables 2 shows pre-post differences in IVA/CPT variables for each therapeutic 
condition separately. 
PLEASE INSERT TABLE 2 ABOUT HERE 
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When analyzing the performance of children treated by NF in IVA/CPT, we found 
significant differences in 15 out of 18 measures. Improving was similar both with visual 
stimuli (all the measures) as auditory (all except three, with two of them with p = .05). 
Children significantly improved in all global measures (except for Auditory Attention, p = 
.05). Effect sizes were large in four visual measures (Visual Response Control, Focus Visual, 
Speed Visual, and Visual Attention), and one auditory measure (Auditory Attention). Most of 
the remaining effect sizes were medium. To sum up, NF was able to improve almost all the 
IVA/CPT measures with a larger average global effect size (d = 0.80), ranging from 0.47 to 
1.03. 
When analyzing the results of PH treatment in IVA/CPT, we found significant 
differences in 11 out of 18 measures with large or very large effect sizes. Children 
significantly improved in all Attention Global Scales, but only in one Response Control 
Global Scale (Auditory). Also, we found significant differences in auditory stimuli but not 
visual in four variables: Response Control, Prudence, Stamina, and Vigilance. Differences 
were found in both stimuli in Full Scale Attention, Focus and Speed. Therefore two results 
should be highlighted: first, improvements in response control were only significant in 
auditory stimuli. And, second, improvements in attention ability were more extensive 
(auditory and visual stimuli) and relevant. As shown Table 2, the average effect size for 
attention was very large (d = 1.42), while for response control was medium (d = 0.73). 
 When analyzing the results of BT treatment in IVA/CPT, we also found significant 
differences in 11 out of 18 measures. The improvements in Global Scales were in Auditory 
Response Control and Auditory Attention, although it was also significant in Full Scale 
Attention (p = .047). It is remarkable that significant differences were found in all the 
primary scales with auditory stimuli (except for Focus, p = .054). On the other hand, this was 
the case only for three measures with visual stimuli. As shown Table 2, the average effect 
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size of behavior therapy is d = 0.75 (medium), and it is slightly larger for attention variables 
(d = 0.77) than for behavior variables (d = 0.72). 
 Tables 3 shows pre-post differences in mother and teachers ADHD measures for each 
therapeutic condition separately. 
PLEASE INSERT TABLE 3 ABOUT HERE 
After NF treatment, significant differences were observed in 5 out 8 measures. 
Teachers showed improvements in hyperactivity, inattention and total score with large effect 
sizes. Instead, there were no significant differences in mothers ADHD RS-IV, and the 
significant differences found in ADDES showed a medium effect size for both hyperactivity 
and inattention subscales. 
No significant differences were found in the mothers and teacher reports of children 
who have received PH treatment using the ADHD RS-IV scale. However, significant 
differences were observed in two mothers ADDES measures with medium effect sizes.  
After BT treatment, there are significant differences in all the teachers and mothers 
measures. Large effect sizes were found in attention and total score teacher measures. The 
remaining measures showed an effect size equal or higher to 0.64. 
Between treatments comparisons based in pre-post change variable. 
For the second objective, the results of the inter-treatment comparisons based on 
ANOVA show that there have not been significant differences among the three treatments in 
parents and teachers rating scales. Instead, it has been found significant differences in 6 out 9 
of variables measured by IVA/CPT (see table 4).  
PLEASE INSERT TABLE 4 ABOUT HERE 
The results reveal that treatments differ significantly only in the variables related to 
attention (no in response control), and these differences are quite favorable to PH 
intervention. Then, as seen in table 4, the post hoc analysis performed with Bonferroni, at 
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confidence level of .05, indicates that PH treatment was superior to NF and BT in Full Scale 
Attention, Auditory Attention, and Visual Vigilance, and was superior to BT in Visual 
Attention. BT was superior to NF in Full Scale Attention and Auditory Attention, and was 
superior to PH only in Vigilance Auditory. NF was superior to PH in Visual Attention and 
Vigilance Auditory. Post hoc differences did not reach significance in Speed Auditory, but 
PH was superior to NF and BT with large effect sizes similar to those found in the 
aforementioned measures. 
 
Discussion 
The first objective of this study was to determine the differential efficacy of 
neurofeedback, pharmacology, and behavior therapy on ADHD neuropsychological measures 
and rating scales for parents and teachers. In relation to this objective we can conclude that 
separately the three treatments were able to generate changes and improvements in most of 
measures. Regarding neurofeedback and methylphenidate data are consistent with those 
obtained by Fuchs et al. (2003), and now we can add the positive data relating to behavior 
therapy. However, the scope of these improvements varies according to how efficacy is 
assessed (inattention or hyperactivity/impulsivity measured by IVA/CPT or rating scales) and 
the source of information consulted (mothers or teachers). 
 In terms of a child’s performance on IVA/CPT task, the three treatments may be 
considered relatively effective with similar effect sizes, but including some different trends. 
Thus, coinciding with Arns et al. (2009), neurofeedback improves response control 
(impulsivity) and attention, although the improvement is greater when the child responds to 
visual stimuli, as deBeus and Kaiser (2011) noted previously. Instead, the effect of 
pharmacological treatment can especially be seen in attention symptomatology regardless of 
the type of stimulation used. However, there is a differential effect in response control (i.e., 
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hyperactivity/impulsivity behaviors) depending on the type of stimulation presented, with 
greater response inhibition when children are asked to respond to auditory stimuli. These 
results are consistent with findings from Fuchs et al. (2003) and Duric et al. (2012), although 
now the data comes from a randomized trial. 
 Regarding behavior therapy, findings are particularly relevant since it is not a 
treatment usually proposed for improving neuropsychological measures. The results show a 
therapeutic success similar for the response control and attention variables, but particularly 
with auditory stimuli. Effect sizes are slightly lower than those of pharmacology, and similar 
to neurofeedback.  
 The ADHD primary symptomatology assessed by parents and teachers scales was 
also significantly improved for the three treatments, although behavioral therapy was 
appreciably superior.  
 The effects of neurofeedback can mainly be seen in hyperactive/impulsive 
symptomatology. In comparison with previous studies, the effect size values for both 
hyperactive-impulsive as well as attention symptoms are closer to those found in Leins et al. 
(2007). When the source consulted are parents, results obtained are similar to Gevensleben et 
al. (2009), but differ from those found in other studies (Duric et al., 2012). In comparison 
with Leins et al. (2007), neurofeedback yields better results when the information is provided 
by the teacher. The effects of pharmacological treatment have been relevant in mother’s 
inattention measures and in ADDES hyperactivity subscale, but no improvement has been 
shown by teachers. Therefore, to some extent neurofeedback and pharmacology showed 
similar results, as in Duric et al (2012) study, but it should be highlighted the superiority of 
neurofeedback in teachers ADHD measures. Finally, behavior therapy showed a significant 
improvement in all rating scales, once again demonstrating its effectiveness in such ADHD 
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measures (Coates, Taylor and Sayal, 2015; Fabiano et al., 2009; Hodgson, Hutchinson and 
Denson, 2012); Willis et al. 2011). 
 The second objective of this study was to compare the improvement of post-treatment 
change among the three treatments. There were not any significant differences either rating 
scales, nor response control, but pharmacology was quite superior in attention ability 
measured by IVA/CPT: its improvement was larger than BT and/or NF in five variables (not 
influenced by the type stimulus presented). Neurofeedback and behavior therapy only were 
able to be superior in two and three measures, respectively. 
 The main implications of these findings are clinical: pharmacology, behavior therapy 
and neurofeedback ca be useful to improve ADHD primary symptomatology, but with 
differential effects. Data are quite consistent with previous studies and neurofeedback seems 
able to improve attention, hyperactivity and impulsivity measures, but especially with visual 
stimuli and with teachers in rating scales. Meanwhile, pharmacology is particularly powerful 
in improving attention ability and attention behaviors in mothers rating scales. But its effects 
are quite lower in response control and hyperactivity. By contrast the effect of behavior 
therapy is more widespread among all the measures used. As it might be expected, the 
intervention improves all inattention and hyperactivity rating scales measures. But perhaps 
more surprisingly, it also has positive effects on response control and attention abilities. 
Therefore, from a global point of view we could consider that behavior therapy has 
the most desirable results (although it can be promptly surpassed on some measures by the 
other two treatments). According to Pfiffner et al. (2013), the strategies that are currently 
applied at school for ADHD are not based on scientific evidence, as they do not consider the 
cognitive limitations that these students suffer, being their application not systematic enough 
to consolidate therapeutic effects and despite evidence of the need for interventions that 
promote self-control. Results found in this study support the combined treatment of ADHD 
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with systematic behavioral training for parents and teachers as the main axis, and, depending 
on the characteristics of each case, we have the power of pharmacology to improve overall 
inattention, and the neurofeedback capacity to also improve control response in cognitive 
tasks. 
Moreover, from the results another implication can also be highlighted in educative 
practice. The findings of this study suggests that adults must provide aural instructions to 
guide the child’s performance and behavior, because, as can be noted, aural stimulation 
improves a child’s attention to the task and helps reduce errors of omission. In response 
control, only measures based on auditory stimuli have been improved by pharmacology. 
Therefore, more emphasis should be placed on the assessment and intervention of auditory 
stimuli in ADHD. 
The main limitations of this study are: (1) samples are too small to rely on statistical 
significance, although the results based on effect sizes can compensate for relatively this fact; 
(2) a similar study should be done with different ADHD subtypes, since this variable can 
have a decisive influence; (3) greater control of comorbid symptoms of ADHD participants 
would also be highly desirable; and (4), follow-up studies are necessary to properly analyze 
the treatments effects. 
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Table 1.  
Demographic and clinical characteristics of the participants. 
 
NEUROFEEDBACK  
GROUP 
(N = 19) 
BEHAVIORAL 
GROUP 
(N = 19) 
PHARMACOLOGICAL 
GROUP 
(N = 19) 
AGE (M ± SD) 9.21± 1.9 8.11± 1.3 9.21± 2.2 
% SEX (boys/girls) 79/21 74/26 79/21 
Clinical Presentation 
DSM V (N) 
      
Combined presentation 7 (36.84%) 5 (26.31%) 8 (42.10%) 
Inattentive presentation 8 (42.10%) 11 (57.89%) 8 (42.10%) 
Hyperactive-Impulsive 
presentation  
4 (21.05%) 3 (15.78%) 3 (15.78%) 
IQ (K-BIT) (M ± SD)       
Crystallized (Verbal) 106.79±12.8 100.81±12 101.70±12.5 
Fluid (Nonverbal) 101.93±11.8 97.94±17.7 93.3±10.8 
IQ Composite 103.36±13 96.94±14.5 94.70±12.9 
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Table 2.  
Pre-post comparison on IVA/CPT measures in each treatment 
 Pre-treatment Post-treatment   
Measures M SD M SD t d 
NEUROFEEDBACK      
FS_RC 98.15 8.72 103.61 10.03 -2.50* 0.69 
A_RC 101.57 11.88 108.35 11.65 -2.94* 0.78 
V_RC 94.84 11.73 102.23 10.59 -3.73** 1.03 
PR_A 103.85 11.21 108.14 8.34 -2.18* 0.58 
PR_V 98.92 12.63 105.15 12.22 -2.81* 0.78 
CON_A 97.28 13.23 101.28 15.56 -2.12 0.56 
CON_V 93.23 13.33 101.53 11.40 -2.39* 0.66 
STA_A 101.50 20.27 111.42 13.42 -2.95* 0.78 
STA_V 98.38 13.49 104.84 16.49 -2.50* 0.69 
FS_AT 92.30 13.37 95.92 15.21 -2.27* 0.63 
A_AT 93.78 17.38 97.92 20.55 -2.15 0.57 
V_AT 92.76 10.98 98.38 10.61 -2.91* 0.80 
VIG_A 88.92 19.50 92.85 20.83 -1.77 0.47 
VIG_V 92.12 12.54 97.30 14.12 -2.34* 0.63 
FOC_A 92.00 11.85 101.14 14.55 -3.30** 0.88 
FOC_V 92.76 9.24 99.07 6.33 -3.20** 0.89 
SPE_A 107.78 15.04 111.35 13.81 -2.20* 0.58 
SPE_V 99.46 12.73 102.38 12.56 -3.01 0.83 
PHARMACOLOGY 
     
FS_RC 95.75 21.19 106.00 7.46 -1.78 0.63 
A_RC 87.70 23.71 101.70 19.68 -2.47* 0.78 
V_RC 100.12 16.03 107.37 6.86 -1.96 0.69 
PR_A 90.30 22.56 105.50 15.50 -3.41** 1.07 
PR_V 94.87 12.02 100.62 9.22 -1.67 0.59 
CON_A 95,75 11.58 100.75 12.33 -1.93 0.68 
CON_V 79.70 19.62 95.30 13.82 -3.13 0.99 
STA_A 109.87 25.26 116.12 17.78 -1.88 0.66 
STA_V 107.4 25.50 109 23.49 -0.44 0.14 
FS_AT 74.87 22.85 99.87 19.35 -4.78** 1.69 
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A_AT 76.55 25.07 100.55 24.86 -4.96*** 1.65 
V_AT 80.50 17.18 102.12 13.89 -3.35* 1.18 
VIG_A 59.90 35.70 92 27.75 -4.44** 1.40 
VIG_V 84.20 18.56 95 15.32 -2.93* 0.92 
FOC_A 92.12 15.31 103.5 9.94 -1.86 0.65 
FOC_V 73.37 22.39 97.87 17.82 -3.20** 1.14 
SPE_A 101.00 9.14 112.2 11.47 -2.78* 0.88 
SPE_V 92.87 7.77 104.25 11.18 -2.43* 0.86 
BEHAVIOR THERAPY 
     
FS_RC 97.40 16.62 102.00 13.78 -2.20 0.69 
A_RC 89.40 15.76 100.46 15.92 -4.35*** 0.95 
V_RC 100.5 18.29 105.00 13.96 -1.58 0.49 
PR_A 99.33 15.96 108.53 12.59 -2.59* 0.67 
PR_V 101.80 17.24 109.40 10.33 -1.76 0.55 
CON_A 82.06 16.36 92.26 16.24 -3.64** 0.94 
CON_V 103.8 13.25 107.30 11.88 -2.48* 0.78 
STA_A 96.80 15 105.20 17.07 -3.21** 0.83 
STA_V 94.90 17.37 97.60 15.32 -1.71 0.54 
FS_AT 84.40 15.98 92.30 16.30 -2.29* 0.72 
A_AT 74.53 20.66 88.13 21.66 -3.46** 0.89 
V_AT 92.60 11.94 99.30 10.70 -2.09 0.66 
VIG_A 69.42 9.40 90.35 21.11 -2.69* 0.72 
VIG_V 100.8 15.02 107.50 10.73 -2.57* 0.81 
FOC_A 87.13 18.09 96.93 16.32 -3.26** 0.85 
FOC_V 95.10 10.88 101.90 6.83 -1.79 0.56 
SPE_A 100.66 14.50 103.60 12.65 -2.10 0.50 
SPE_V 86.90 6.83 93.20 14.77 -2.69* 0.85 
Note: FS_RC = Full Scale Response Control; A_RC = Auditory Response Control, V_RC =Visual 
Response control; PR_A =Prudence Auditory; PR_V = Prudence Visual; CON_A = Consistency 
Auditory; CON_V =Consistency Visual; STA_A = Stamina Auditory; STA_V = Stamina Visual; 
FS_AT = Full Scale Attention; A_AT = Auditory Attention; V_AT = Visual Attention; VIG_A = 
Vigilance Auditory; VIG_V = Vigilance Visual; FOC_A = Focus Auditory; FOC_V = Focus Visual; 
SPE_A = Speed Auditory; SPE_V = Speed Visual. 
*p ≤ .05; ** p ≤ .01; ***p ≤ .001. d: Cohen´s Effect Size. 
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Table 3.  
Pre-post comparisons on ADHD rating scales in each treatment. 
 Neurofeedback (N = 19) Pharmacology (N = 19) Behavior Therapy (N = 19) 
 Pre. Post.   Pre. Post.   Pre. Post.   
 M SD M SD t d M SD M SD t d M SD M SD t d 
ADHD RS-IV Mothers 
HI 17.43 4.98 14.21 6.77 2.08 0.59 12.40 8.69 8.80 5.82 1.25 0.42 15.38 6.66 9.94 5.42 3.43** 0.76 
IN 17.64 4.63 15.86 6.81 1.01 0.34 19.30 5.41 14.40 3.83 2.11 0.85 19.75 5.07 14.31 6.41 3.46** 0.64 
TS 35.07 8.18 30.07 13.05 1.62 0.43 31.70 13.30 23.20 9.64 1.72 0.55 35.13 11.08 24.25 1.22 3.75** 0.70 
ADHD RS-IV Teachers 
HI 17 9.09 10.86 8.35 3.15* 1.34 9.83 7.88 6.83 4.57 1.16 0.37 12.10 7.53 12.10 7.53 3.61** 0.74 
IN 20.43 4.89 14.14 5.30 2.33 0.94 17.50 8.09 15.67 4.03 0.58 0.22 13.90 5.19 13.90 5.19 3.46** 1.54 
TS 37.43 9.55 25 12.83 3.11* 1.21 27.33 14.80 22.50 7.06 0.95 0.31 26.00 11.90 26.00 11.90 3.88** 1.11 
ADDES Mothers 
HI 47.38 20.86 38.63 19.42 2.20* 0.58 33.55 22.22 21.00 20.01 2.44* 0.71 44.94 28.38 30.63 24.22 3.21** 0.79 
IN 54.25 14.90 45.63 16.29 2.29* 0.61 50.91 14.43 38.09 21.61 2.49* 0.72 55.88 20.90 36.25 20.29 2.93*** 0.73 
Note: HI = Hyperactivity/Impulsivity, IN =Inattention, TS = Total Score. 
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Table 4.  
Post hoc comparisons between treatments on IVA/CPT variables. 
Change Variable Treatments Mean Diff. SE p 95% CI d 
Full Scale Attention NF vs PH -21.38 4,64 .001 9.56-33.20 2.09 
 NF vs BT -4.28 4,34 .998 -15.34-6.78 0.50 
 PH vs BT 17.10 4.90 .005 4.62-29.57 1.47 
Auditory Attention NF vs PH -19.85 5.40 .002 -33.44-.6.7 1.80 
 NF vs BT -9.45 4.69 .156 -21.27-2.35 0.76 
 PH vs BT 10.40 5.33 .177 -3.00-23.80 0.75 
Visual Attention NF vs PH 15.63 5.22 .017 2.32-28.94 1.19 
 NF vs BT -1.08 4.89 1.00 -13.54-11.37 0.12 
 PH vs BT 14,55 5,51 .041 0.49-28.60 1.03 
Vigilance Auditory NF vs PH 23.12 7.93 .019 3.13-43.11 1.00 
 NF vs BT -10.22 7.38 .525 -28.82-8.36 0.96 
 PH vs BT -33.35 8.06 .001 -53.66-13.04 1.07 
Vigilance Visual NF vs PH -19.19 6.09 .011 -34.67-3.70 1.19 
 NF vs BT -0.78 5.55 1.00 -14.90-13.33 0.10 
 PH vs BT 18.40 6.30 .020 2.39-34.42 1.07 
Speed Auditory NF vs PH -7.62 3.33 .084 -16.00-.74 0.84 
 NF vs BT 0.63 2.99 1.00 -687-8.15 0.18 
 PH vs BT 8.26 3.28 .050 .009-16.52 0.97 
Note: NF = Neurofeedback; PH = Pharmacology; BT = Behavior Therapy. d = Cohen’s Effect Size. 
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Figure 1.  
Distribution of the participants in the study. 
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Children ages 7-14 with suspected ADHD 
(screening) 
(n = 146) Excluded by inclusión criteria (n =  52) 
Criterion 1: Age  < 7 years (n = 8) 
Criterion 2: Don´t meet diagnostic criteria (n = 35) 
Criterion 6: Comorbid medical condition (n = 9) 
Incorporated into the study 
(n = 94) 
Randomization (n = 59) 
Had no interest in participating (n = 35) 
Reason: 
-Trouble getting around (n = 20) 
- Matching parental occupation (n = 10) 
- Other (n = 5) 
Pharmacological Treatment 
(n = 19) 
Neurofeedback 
(n =  21) 
Behavior Therapy 
(n = 19) 
Pre- Treatment Evaluation n = 19 n = 21 n = 19 
     Post- Treatment Evaluation n = 19 n = 19 
n = 19 
